<section number="58-37-303"><effdate>5/6/2026</effdate><histories><history>Renumbered and Amended by Chapter <modchap sess="2026GS">362</modchap>, 2026 General Session</history><modyear>2026</modyear></histories><catchline>Continuing education for controlled substance prescribers.</catchline><subsection number="58-37-303(1)">For the purposes of this section:<subsection number="58-37-303(1)(a)">"Controlled substance prescriber" means an individual, other than a veterinarian, who:<subsection number="58-37-303(1)(a)(i)">is licensed to prescribe a controlled substance under this chapter; and</subsection><subsection number="58-37-303(1)(a)(ii)">possesses the authority, in accordance with the individual's scope of practice, to prescribe schedule II controlled substances and schedule III controlled substances that are applicable to opioid narcotics, hypnotic depressants, or psychostimulants.</subsection></subsection><subsection number="58-37-303(1)(b)">"D.O." means an osteopathic physician and surgeon licensed under <xref depth="1" refnumber="58-68" start="1">Chapter 68, Utah Osteopathic Medical Practice Act</xref>.</subsection><subsection number="58-37-303(1)(c)">"FDA" means the United States Food and Drug Administration.</subsection><subsection number="58-37-303(1)(d)">"M.D." means a physician and surgeon licensed under <xref depth="1" refnumber="58-67" start="1">Chapter 67, Utah Medical Practice Act</xref>.</subsection><subsection number="58-37-303(1)(e)">"SBIRT" means the Screening, Brief Intervention, and Referral to Treatment approach used by the federal Substance Abuse and Mental Health Services Administration or defined by the division, in consultation with the Office of Substance Use and Mental Health, by administrative rule, in accordance with <xref depth="1" refnumber="63G-3" start="0">Title 63G, Chapter 3, Utah Administrative Rulemaking Act</xref>.</subsection></subsection><subsection number="58-37-303(2)"><subsection number="58-37-303(2)(a)">Beginning with the licensing period that begins after January 1, 2014, as a condition precedent for license renewal, each controlled substance prescriber shall complete at least 3.5 continuing education hours per licensing period that satisfy the requirements of Subsection <xref depth="4" refnumber="58-37-6.5(3)" start="0">(3)</xref>.</subsection><subsection number="58-37-303(2)(b)"><subsection number="58-37-303(2)(b)(i)">Beginning with the licensing period that begins after January 1, 2024, as a condition precedent for license renewal, each controlled substance prescriber shall complete at least 3.5 continuing education hours in an SBIRT-training class that satisfies the requirements of Subsection <xref depth="4" refnumber="58-37-6.5(4)" start="0">(4)</xref>.</subsection><subsection number="58-37-303(2)(b)(ii)">Completion of the SBIRT-training class, in compliance with Subsection <xref depth="4" refnumber="58-37-6.5(2)(b)(i)" start="0">(2)(b)(i)</xref>, fulfills the continuing education hours requirement in Subsection <xref depth="4" refnumber="58-37-6.5(3)" start="0">(3)</xref> for the licensing period in which the class was completed.</subsection><subsection number="58-37-303(2)(b)(iii)">A controlled substance prescriber:<subsection number="58-37-303(2)(b)(iii)(A)">need only take the SBIRT-training class once during the controlled substance prescriber's licensure in the state; and</subsection><subsection number="58-37-303(2)(b)(iii)(B)">shall provide a completion record of the SBIRT-training class in order to be reimbursed for SBIRT services to patients, in accordance with Sections <xref depth="3" refnumber="26B-3-131" start="0">26B-3-131</xref> and <xref depth="3" refnumber="49-20-416" start="0">49-20-416</xref>.</subsection></subsection></subsection></subsection><subsection number="58-37-303(3)">A controlled substance prescriber shall complete at least 3.5 hours of continuing education in one or more controlled substance prescribing classes, except dentists, who shall complete at least two hours, that satisfy the requirements of Subsections <xref depth="4" refnumber="58-37-6.5(4)" start="0">(4)</xref> and <xref depth="4" refnumber="58-37-6.5(6)" start="0">(6)</xref>.</subsection><subsection number="58-37-303(4)">A controlled substance prescribing class shall:<subsection number="58-37-303(4)(a)">satisfy the division's requirements for the continuing education required for the renewal of the controlled substance prescriber's respective license type;</subsection><subsection number="58-37-303(4)(b)">be delivered by an accredited or approved continuing education provider recognized by the division as offering continuing education appropriate for the controlled substance prescriber's respective license type; and</subsection><subsection number="58-37-303(4)(c)">include a postcourse knowledge assessment.</subsection></subsection><subsection number="58-37-303(5)">An M.D. or D.O. completing continuing professional education hours under Subsection <xref depth="4" refnumber="58-37-6.5(4)" start="0">(4)</xref> shall complete those hours in classes that qualify for the American Medical Association Physician's Recognition Award Category 1 Credit.</subsection><subsection number="58-37-303(6)">The 3.5 hours of the controlled substance prescribing classes under Subsection <xref depth="4" refnumber="58-37-6.5(4)" start="0">(4)</xref> shall include educational content covering the following:<subsection number="58-37-303(6)(a)">the scope of the controlled substance abuse problem in Utah and the nation;</subsection><subsection number="58-37-303(6)(b)">all elements of the FDA Blueprint for Prescriber Education under the FDA's Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, as published July 9, 2012, or as it may be subsequently revised;</subsection><subsection number="58-37-303(6)(c)">the national and Utah-specific resources available to prescribers to assist in appropriate controlled substance and opioid prescribing;</subsection><subsection number="58-37-303(6)(d)">patient record documentation for controlled substance and opioid prescribing;</subsection><subsection number="58-37-303(6)(e)">office policies, procedures, and implementation; and</subsection><subsection number="58-37-303(6)(f)">some training regarding medical cannabis, as that term is defined in Section <xref depth="3" refnumber="26B-4-201" start="0">26B-4-201</xref>.</subsection></subsection><subsection number="58-37-303(7)"><subsection number="58-37-303(7)(a)">The division, in consultation with the Utah Medical Association Foundation, shall determine whether a particular controlled substance prescribing class satisfies the educational content requirements of Subsections <xref depth="4" refnumber="58-37-6.5(4)" start="0">(4)</xref> and <xref depth="4" refnumber="58-37-6.5(6)" start="0">(6)</xref> for an M.D. or D.O.</subsection><subsection number="58-37-303(7)(b)">The division, in consultation with the applicable professional licensing boards, shall determine whether a particular controlled substance prescribing class satisfies the educational content requirements of Subsections <xref depth="4" refnumber="58-37-6.5(4)" start="0">(4)</xref> and <xref depth="4" refnumber="58-37-6.5(6)" start="0">(6)</xref> for a controlled substance prescriber other than an M.D. or D.O.</subsection><subsection number="58-37-303(7)(c)">The division may by rule establish a committee that may audit compliance with the Utah Risk Evaluation and Mitigation Strategy (REMS) Educational Programming Project grant, that satisfies the educational content requirements of Subsections <xref depth="4" refnumber="58-37-6.5(4)" start="0">(4)</xref> and <xref depth="4" refnumber="58-37-6.5(6)" start="0">(6)</xref> for a controlled substance prescriber.</subsection><subsection number="58-37-303(7)(d)">The division shall consult with the Department of Health and Human Services regarding the medical cannabis training described in Subsection <xref depth="4" refnumber="58-37-6.5(6)(f)" start="0">(6)(f)</xref>.</subsection></subsection><subsection number="58-37-303(8)">A controlled substance prescribing class required under this section:<subsection number="58-37-303(8)(a)">may be held:<subsection number="58-37-303(8)(a)(i)">in conjunction with other continuing professional education programs; and</subsection><subsection number="58-37-303(8)(a)(ii)">online; and</subsection></subsection><subsection number="58-37-303(8)(b)">does not increase the total number of state-required continuing professional education hours required for prescriber licensing.</subsection></subsection><subsection number="58-37-303(9)">The division may establish rules, in accordance with <xref depth="1" refnumber="63G-3" start="0">Title 63G, Chapter 3, Utah Administrative Rulemaking Act</xref>, to implement this section.</subsection><subsection number="58-37-303(10)">A controlled substance prescriber who, on or after July 1, 2017, obtains a waiver to treat opioid dependency with narcotic medications, in accordance with the Drug Addiction Treatment Act of 2000, 21 U.S.C. Sec. 823 et seq., may use the waiver to satisfy the 3.5 hours of the continuing education requirement under Subsection <xref depth="4" refnumber="58-37-6.5(3)" start="0">(3)</xref> for two consecutive licensing periods.</subsection></section>